Crossmark

Commentary on “Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”

Crossref DOI link: https://doi.org/10.1038/s41443-023-00811-4

Published Online: 2023-12-18

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Manfredi, Celeste https://orcid.org/0000-0002-9706-8516
Bologna, Eugenio

Licari, Leslie Claire
License Information

Text and Data Mining valid from 2023-12-18

Version of Record valid from 2023-12-18
More Information

Article History

Received: 28 November 2023

Revised: 1 December 2023

Accepted: 6 December 2023

First Online: 18 December 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below